Specialty Interests
Prostate cancer etiology and genetics, viral pathogenesis
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 1/16/2008, Dr.
Silverman has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Royalty Payments. Dr. Silverman has the right to receive royalty payments for inventions or discoveries related to the companies shown below:
Abcam
Affymetrix
Alios BioPharma, Inc.
Axxora
Hycult Biotechnology
Invitrogen
Novus Biologicals
Santa Cruz
Upstate USA
Abbott Laboratories, Inc.
Equity. Dr. Silverman owns stock or stock options in the following companies for activities as a founder, inventor, or consultant:
Alios BioPharma, Inc.
